H.C. Wainwright lowered the firm’s price target on Kezar Life Sciences to $7 from $20 and keeps a Buy rating on the shares. The firm reduced estimates to reflect the company’s near-term outlook and changing market dynamics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.